PMID: 11318107Apr 25, 2001Paper

Chloroplast transformation in Euglena gracilis: splicing of a group III twintron transcribed from a transgenic psbK operon

Current Genetics
N A DoetschR B Hallick

Abstract

The Escherichia coli aadA gene product, which confers resistance to spectinomycin and streptomycin, has been widely used as a dominant selectable marker for chloroplast transformation of Chlamydomonas and tobacco. An aadA transformation cassette was adapted for expression in Euglena gracilis chloroplasts by replacing the Chlamydomonas promoter and 3' untranslated region (UTR) with the E. gracilis psbA promoter and 3' UTR. Transgenic DNA was introduced into E. gracilis chloroplasts by biolistic transformation. Streptomycin- and spectinomycin-resistant colonies were obtained, which screened positively for the presence of the transforming vector by PCR amplification. Although integration of the transforming DNA into the chloroplast genome was not detected, transforming DNA was stably maintained in the chloroplast as an episomal element during continuous selection on antibiotics. The aadA cassette was also inserted into a transformation vector which contained the independently expressed psbK operon from either E. gracilis or a closely related species, E. stellata. The psbK operon contained at least two group III introns and a group III twintron, was highly expressed, and was only 1.5 kb in length. In transgenic E. gracilis chloropl...Continue Reading

Citations

Sep 2, 2005·Plant Cell Reports·Tara L WalkerChris Collet
Sep 2, 2011·Journal of Industrial Microbiology & Biotechnology·Yangmin GongHong Gao
Apr 15, 2008·Médecine sciences : M/S·Jean-Paul CadoretAude Carlier
Feb 9, 2010·Eukaryotic Cell·Randor RadakovitsMatthew C Posewitz
Nov 6, 2008·Annual Review of Genetics·Micaela S ParkerE Virginia Armbrust
Aug 12, 2005·Cytogenetic and Genome Research·A R Robart, S Zimmerly
Aug 13, 2011·Biofuels·Michael HannonStephen Mayfield
Sep 21, 2001·Journal of Molecular Biology·R Bock
Mar 24, 2011·Plant Biotechnology Journal·Anil Day, Michel Goldschmidt-Clermont
Oct 1, 2013·Journal of Phycology·Peter G Kroth
Aug 1, 2012·Journal of Phycology·Carla L GutiérrezVitalia Henríquez
May 6, 2016·Frontiers in Plant Science·Lior DoronMichal Shapira
Jun 21, 2016·International Journal of Molecular Sciences·Na YanZanmin Hu
Nov 25, 2005·Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology·Pal Maliga
Oct 4, 2019·The New Phytologist·Anna M G Novák VanclováVladimír Hampl
Aug 21, 2003·Molecular Genetics and Genomics : MGG·H MireauT D Fox
Sep 21, 2019·Biotechnology and Applied Biochemistry·Ayesha SiddiquiNiaz Ahmad
Jul 28, 2020·Biotechnology and Bioengineering·Bishal KhatiwadaHelena Nevalainen
Apr 22, 2017·Plant Methods·Muhamed AdemTileye Feyissa
Jun 4, 2019·Frontiers in Bioengineering and Biotechnology·Alexander GissiblAnwar Sunna
Jul 15, 2020·International Journal of Molecular Sciences·Yihe YuChoun-Sea Lin
Mar 21, 2020·Biotechnology Advances·Yasin Torres-TijiStephen P Mayfield

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.